Genomics Market

Global Genomics Market Size (2022 to 2027)

As per our research report, the global genomics market is predicted to be worth USD 29.02 billion by 2027 from USD 18.1 billion in 2022, growing at a CAGR of 9.9% during the forecast period.

Global Genomics Market Share Insights:

• Based on the product, the consumables segment had the largest share of the global genomics market in 2021.
• The North American genomics market dominated in 2021 and accounted for 45% of the global market share in 2021. The market in this region was valued at USD 5.64 billion in 2021.
• The Asia-Pacific genomics market held a considerable share of the worldwide market in 2021 and is anticipated to grow at a CAGR of 11.89% from 2022 to 2027.
• The European genomics market had a substantial share of the global market in 2021 and is estimated to grow by USD 8.40 billion by 2027.

MARKET DRIVERS:

The growth of the genomics market is majorly driven by increasing technological developments and their rapid adoption among developed and developing countries.

Technological developments such as DNA sequencing have promoted the usage of genomics. In the olden days, genome sequencing consumed significant time and cost. Technological developments such as DNA sequencing have helped notably to reduce the time and cost involved in sequencing the genomes, which has resulted in the growing number of genomes that can be sequenced. In addition, CRISPR gene editing, synthetic biology, and bioinformatics are other notable technological developments that favored the adoption of genomics and have boosted the growth of the genomics market. Likewise, technological developments have generated numerous growth possibilities in the genomics market.

The rising adoption of personalized medicine is anticipated to fuel the genomics market growth.

The adoption and preference towards personalized medicine are growing significantly worldwide. Personalized medicine is a new approach in the healthcare industry. Genomics plays a vital role in developing personalized treatment plans for patients. In this process, the healthcare providers study the patient's genetic makeup and prepare the treatment plan that gives the best outcome and reduces side effects. Personalized medicine is believed to be cost-effective and deliver improved patient safety.

Growing support and investments from governments and private organizations for the R&D of genomics are fuelling the market's growth rate.

In addition, the growing patient population suffering from cancer is expected to boost the growth rate of the genomics market. According to the statistics published by the American Cancer Society, 1.9 million people new cancer cases were expected in 2022. Furthermore, according to the data given by the National Cancer Institute, an estimated 29.5 million people are anticipated to diagnose with cancer every year by 2040. Furthermore, the increasing awareness among healthcare providers regarding the advantages of genomics and the growing demand for genomic services are anticipated to result in market growth during the forecast period.

MARKET RESTRAINTS:

However, the lack of training programs on genomics technologies in research centers significantly hinders the market's growth. In addition, the high cost of genomic research equipment and the lack of trained technicians hamper the growth rate of the genomics market worldwide. In addition, people diagnosed with might be susceptible to developing some diseases in the future. Furthermore, people with genetic disorders may become under pressure not to have children as they can't pass the faulty gene to the next generation, and rigorous rules and regulations by the government regarding the overuse of genetics are some factors impeding the market's growth. Furthermore, concerns associated with ethics and privacy, limited awareness and understanding of genomics, and issues associated with reimbursements in some countries are inhibiting the growth rate of the global genomics market.

Impact of covid-19 on the global genomics market:

The world health organization announced COVID-19 as an emergence in healthcare. The pandemic has shown profound changes in healthcare. COVID-19 has had a favorable impact on the global genomics market growth. Market players have increased their research and development activities and raised investments to develop an efficient treatment for the novel coronavirus. Monitoring the genome sequence of coronavirus helps track the manner of spreading the virus and its effect on the human genome. The collected information can be used to develop an effective treatment for the virus. In addition, the researchers used the virus genome to track the coronavirus infection's origin to develop medicine to treat the virus.

REPORT COVERAGE:

This research report segmented and sub-segmented the global genomics market based on the product, application, technology, process, end-user, and region.

Genomics Market - By Product:

• Instruments/systems
• Consumables
• Services

Based on the product, the consumables segment accounted for the leading share in the global genomics market in 2021 and is likely to display a high growth rate during the forecast period. The increasing number of patients with chronic diseases such as diabetes, cancer, and others is one of the key factors propelling segmental growth. In addition, the prevalence of R&D activities in developing new drugs escalates the segment's growth rate. Furthermore, the growing need for genomic services and rising usage of genomic technologies are expected to result in the segment's growth during the forecast period.

On the other hand, the instruments segment is predicted to witness a healthy CAGR in the coming years owing to the rapid adoption of technological developments to deliver effective genomic services.

The services segment is expected to have an improved occupancy in the global genomics market during the forecast period due to the growing need for data analysis in genomic research.

Genomics Market - By Technology:

• Sequencing
• Microarray Technology
• PCR
• Nucleic Acid Extraction

Based on technology, the PCR segment occupied the largest share of the global genomics market in 2021, and the domination of the segment is likely to continue during the forecast period owing to factors such as increasing adoption of PCR for DNA amplification at reduced costs, technological enhancements, and increasing research investments in genomics. In addition, the growing usage of PCR technology in genomic research is one of the notable factors contributing to segmental growth.

On the other hand, segments such as sequencing and microarray technology are anticipated to hold a considerable share of the global market during the forecast period.

Genomics Market - By Process:

• Library Preparation
• Sequencing
• Imaging
• Data Analysis

Based on the process, the data analysis segment captured the major share of the global genomics market in 2021 and is expected to continue its domination during the forecast period. The growing usage of genomic technologies releases a huge volume of data. In addition, the complexities associated with the genomics data and the increasing need for data analysis in research are majorly propelling the growth rate of the global genomics market.

The imaging segment is estimated to register a healthy CAGR during the forecast period owing to the rising importance of imaging in genomic research and the increasing number of developments in genomic technologies.

Genomics Market - By Application:

• Diagnostics
• Drug Discovery and Development
• Personalized Medicine
• Agriculture & Animal Research

Based on application, the diagnostic testing segment held the major share of the global genomics market. Factors such as increasing health consciousness and growing deaths from genetic diseases are fuelling segmental growth. In addition, increasing disposable income and rising healthcare expenditure contribute to the segment's growth rate.

On the other hand, the personalized medicine segment is projected to showcase the highest CAGR in the global genomics market during the forecast period.

Genomics Market - By End User:

• Research Centres
• Hospitals and Clinics
• Pharmaceutical Companies

Based on end-users, the hospitals and clinics segment occupied a major share of the global genomics market in 2021. The growing competition between the key market participants, the increasing number of hospitals and clinics, and improvements in the healthcare infrastructure in emerging economies are primarily propelling segmental growth.

On the other hand, the research centers segment is predicted to have a notable share in the global market during the forecast period owing to increasing R&D investments, and the growing focus of research centers and key market players to develop innovative technologies and products are the contributions to the growth rate of the segment.

Genomics Market - By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa

The North American genomics market was the largest regional segment worldwide in 2021 and is predicted to occupy the most significant share globally during the forecast period. An increasing number of initiatives and research funding by the North American governments are majorly fuelling regional market growth. In addition, the increasing incidence of genetic disabilities and abnormalities among the population of North American countries is booting the genomics market in North America. The presence of sophisticated healthcare infrastructure in North American countries is another notable factor promoting the genomics market growth in this region. In 2021, the U.S. had the largest share of the North American market, followed by Canada.

Europe's genomics market captured a substantial share of the worldwide genomics market in 2021 and is forecasted to register a noteworthy CAGR between 2022 to 2027. The rapid adoption of technological developments in the genomics field, availability of substantial funding for genomic R&D, and increasing adoption of personalized medicine propel the European genomics market growth. In addition, the rising patient population suffering from chronic diseases is contributing to the growth of the European market. Companies such as Illumina, QIAGEN, and Thermo Fisher Scientific play a notable role in the European genomics market.

The Asia Pacific genomics market is a potential market for genomics and is anticipated to showcase the fastest CAGR during the forecast period. The presence of a large patient population and the increasing adoption of technological advancements in the healthcare industry is favoring the market growth in APAC. In addition, increasing government support in investments and favorable policies for genomic research is promoting the growth rate of the genomics market in the APAC region.

The Latin American genomics market is predicted to grow steadily during the forecast period. The Brazilian and Mexican genomics markets are expected to account for most of the share in this regional market during the forecast period.

The MEA genomics market is standing at a nascent stage. Still, they will show inclined growth in the future because of growing investment by government bodies, funding agencies, and biotechnology companies anticipated to drive the market in this region.

KEY MARKET PARTICIPANTS AND SHARE INSIGHTS:

In this report, companies playing a promising role in the global genomics market are Affymetrix, Inc., Agilent Technologies, BGI, Thermo Fisher Scientific, Bio-Rad Laboratories Inc., G.E. Healthcare, Illumina Inc., Qiagen, Roche Diagnostics, Life Technologies, and Cepheid.

RECENT HAPPENINGS IN THIS MARKET:

• In February 2023, Complete Genomics, a U.S.-based firm, announced the launch of DNBSEQ-T20, a genetic sequencer that claimed it would generate the first sub-$100  genome with low to mid-range throughput.
• In July 2020, Illumina launched TruSight Software Suite, which supplies ready-made infrastructure to recognize the potentiality of whole-genome sequencing for odd diseases.
• In June 2019, BGI Genomics and Eluthia partnered to develop reproductive genetics for the German market. The agreement offers the nonintrusive prenatal NIFTY test in Germany in the name of PreviaTst.
• In November 2018, Illumia, Inc. acquired Pacific Biosciences at USD 8.00 per share. The acquisition complements Illumina sequencing with appropriate long-read sequencing abilities to answer genomic-related questions.
• In March 2017, Bristol-Myers Squibb Company collaborated with Foundation Medicine Company to deploy comprehensive genomic profiling and molecular information solutions offered by Foundation Medicine to identify predictive biomarkers like TMB and MSI to escalate its immunotherapy clinical trials. 
• In January 2017, my B.D. Launched WTA reagents. These are used for single-cell analysis as they offer uncomplicated quantification of genetic information and high accuracy.
• In June 2016, VWR entered a distribution agreement with SGI-DNA to distribute reagents in Europe and North America.